Keizo Koya is Sr. VP & Drug Development at SYNTA PHARMACEUTICALS CORP (SNTA). They have made 1 open-market trade across 1 company since 2009, most recently 2012-03-01.
CIK 0001325718
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $28K since 2009, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| SNTA | 12,999 | — |
Shares reported on the most recent Form 4, priced at the 2012-03-05 close. 1 holding could not be priced and is excluded from the total.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.